- Home
- FOLD vs CPRX Comparison
FOLD vs CPRX Comparison
Compare FOLD & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- CPRX
- Stock Information
- Founded
- FOLD 2002
- CPRX 2002
- Country
- FOLD United States
- CPRX United States
- Employees
- FOLD N/A
- CPRX 167
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FOLD Health Care
- CPRX Health Care
- Exchange
- FOLD Nasdaq
- CPRX Nasdaq
- Market Cap
- FOLD 2.9B
- CPRX 2.6B
- IPO Year
- FOLD 2007
- CPRX 2006
- Fundamental
- Price
- FOLD $6.32
- CPRX $21.12
- Analyst Decision
- FOLD Strong Buy
- CPRX Strong Buy
- Analyst Count
- FOLD 10
- CPRX 6
- Target Price
- FOLD $26.89
- CPRX $32.83
- AVG Volume (30 Days)
- FOLD 4.2M
- CPRX 1.3M
- Earning Date
- FOLD 07-31-2025
- CPRX 08-06-2025
- Dividend Yield
- FOLD N/A
- CPRX N/A
- EPS Growth
- FOLD N/A
- CPRX 178.13
- EPS
- FOLD N/A
- CPRX 1.57
- Revenue
- FOLD $571,160,000.00
- CPRX $534,645,999.00
- Revenue This Year
- FOLD $19.97
- CPRX $16.37
- Revenue Next Year
- FOLD $22.92
- CPRX $8.80
- P/E Ratio
- FOLD N/A
- CPRX $13.47
- Revenue Growth
- FOLD 32.29
- CPRX 29.97
- 52 Week Low
- FOLD $5.51
- CPRX $15.34
- 52 Week High
- FOLD $12.65
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- FOLD 55.44
- CPRX 43.70
- Support Level
- FOLD $6.06
- CPRX $20.76
- Resistance Level
- FOLD $6.40
- CPRX $21.71
- Average True Range (ATR)
- FOLD 0.28
- CPRX 0.59
- MACD
- FOLD 0.01
- CPRX 0.10
- Stochastic Oscillator
- FOLD 49.44
- CPRX 44.07
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).